TEAM-U: A TargEted MAnageMent Intervention for Reducing Stroke Risk Factors in High Risk Ugandans

Sponsor
Case Western Reserve University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04685408
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (NIH), Fogarty International Center of the National Institute of Health (NIH)
246
3
2
34.6
82
2.4

Study Details

Study Description

Brief Summary

The proposed 2-phase project will first refine the TargetEd MAnageMent (TEAM) intervention to ensure acceptability across a broad range of Ugandans at risk for stroke and then test the effects of TEAM in reducing stroke risk in a 3-site, prospective, 6-month randomized controlled trial (RCT).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: TEAM
  • Behavioral: ETAU
N/A

Detailed Description

In Phase 1 of the project, stakeholder's advisory board (SAB) will be convened across 3 Ugandan sites. The SAB will be composed of up to 15 relevant stakeholders including 3 stroke survivors, 3 individuals with multiple stroke risk factors as defined above, 3 family members, 3 clinicians and 3 administrators who practice in the proposed study enrollment sites. The purpose of the SAB is to refine the TEAM intervention content to meet the needs of patients and professional healthcare stakeholders and suggest how TEAM might best be incorporated into clinical workflow, as well as give guidance and feedback on recruitment methods and advertisements.

Phase 2 of the project will be conducted across 3 Ugandan sites that will enroll a representative sample of Ugandans at risk for stroke (Kiruddu, Nsambya and Mbarara Hospitals and their associated outpatient clinics). In the RCT portion of the study, 246 participants will be randomized at baseline on a 1:1 basis to receive either TEAM (N= 123) or enhanced treatment as usual (ETAU) (N=123) and will be followed for a total of 6 months. Since stroke is a moderately long-term health outcome (years to decades) that typically occurs in the presence of one or more stroke risk factors, the project will focus on testing whether TEAM can modify well-established short-term biomarkers that predict stroke risk, specifically BP control, serum cholesterol and blood glucose control. Secondary outcomes of interest include additional stroke risk biomarkers, (HDL, LDL, triglycerides) diet, exercise, use of alcohol and tobacco, stroke knowledge/attitudes, stress, and treatment adherence with risk-reducing medications. We will also explore associations of age, gender, urban vs. rural residential status and stroke history (prior vs. no previous stroke) on TEAM outcomes. To help inform future scale-up should RCT findings be positive, we will assess barriers and facilitators to TEAM implementation using both qualitative and quantitative methods.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
246 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A TargEted MAnageMent Intervention for Reducing Stroke Risk Factors in High Risk
Actual Study Start Date :
May 13, 2022
Anticipated Primary Completion Date :
Mar 30, 2025
Anticipated Study Completion Date :
Mar 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: TargEted MAnageMent Intervention (TEAM)

This arm will receive the experimental intervention, TargEted MAnageMent Intervention (TEAM)

Behavioral: TEAM
TEAM is informed by principles of social cognitive theory TEAM uses nurses and peer educator dyads (PEDs) composed of patients and their care partners to co-deliver an intervention intended to help reduce future stroke risk. Team begins with one 60-minute 1:1 orientation session, in which the nurse and PED meet with the patient and his/her care partner. This is followed by 6 hour-long group sessions with 6-8 patients and their care partners held approximately weekly. The first orientation session will be done approximately 1 week post baseline, followed by group sessions were done at 2, 4, 6, 8, 10 and 12 weeks post-baseline.

Active Comparator: Enhanced treatment as usual (ETAU)

This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).

Behavioral: ETAU
ETAU will consist of an orientation visit with a nurse who will provide patient-education materials on stroke risk adapted from the American Heart Association materials and cover common risk factors such as hypertension, obesity, high salt/high fat diet and diabetes. Patients will also receive basic written information in their language of preference and tailored to the reading level of most patients at the clinic. Patients will be offered the opportunity to bring a family member with them to this visit who may also ask questions and who can assist them with understanding written materials for those with limited literacy. The nurse in ETAU will then follow-up with participants with a series of 9 brief phone calls spaced out over the course of 6 months (approximately every 2 weeks during months 1 and 2, then approximately monthly thereafter). Content will reinforce materials provided in the orientation visit and the nurse will be available to answer questions that may arise.

Outcome Measures

Primary Outcome Measures

  1. Change from baseline systolic blood pressure (BP) at 6 months [Baseline and 6 months]

    Systolic blood pressure indicates how much pressure your blood is exerting against your artery walls when the heart beats. Higher reading implies more pressure

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age range: ≥ 18 years

  • At risk for stroke defined by the following:

  1. High systolic BP defined as >140 mmHg assessed on at least 2 occasions at least 3 days apart and either criterion b or c as noted below:

  2. At least 1 other modifiable stroke risk factor including: diabetes, hyperlipidemia, obesity, smoking, problem alcohol use or sedentary lifestyle. Problem alcohol use for screening purposes will be assessed with questions on frequency, type of alcohol and quantity consumed. Participants will be classified as engaging in potential problem alcohol use if they exceed the recommended level for safe alcohol intake i.e. more than 3 drinks on average every time they drink, or if they undertook binge drinking (i.e. more than 3 drinks on one occasion in the one month preceding the evaluation).

  3. History of stroke or transient ischemic attack within the past 5 years

  • Able to participate in group sessions
Exclusion Criteria:
  • Individuals who are unable or unwilling to provide written informed consent

  • Individuals who have sickle-cell disease

  • Females who are pregnant or lactating

  • Individuals with dementia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mulago Hospital Kampala Uganda
2 Nsambya Hospital Kampala Uganda
3 Mbarara Regional Referral Hospital Mbarara Uganda

Sponsors and Collaborators

  • Case Western Reserve University
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • Fogarty International Center of the National Institute of Health

Investigators

  • Principal Investigator: Marta Sajatovic, MD, Case Western Reserve University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Martha Sajatovic, MD, Professor, Case Western Reserve University
ClinicalTrials.gov Identifier:
NCT04685408
Other Study ID Numbers:
  • STUDY20200882
  • 1R01NS118544
First Posted:
Dec 28, 2020
Last Update Posted:
May 17, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Martha Sajatovic, MD, Professor, Case Western Reserve University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 17, 2022